Opaleye Management’s Avenue Therapeutics ATXI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
– Sell
-875
Closed -$10.7M – 67
2020
Q3
$10.7M Sell
875
-45
-5% -$547K 2.09% 17
2020
Q2
$11.1M Hold
920
– – 2.25% 15
2020
Q1
$9.25M Hold
920
– – 2.45% 14
2019
Q4
$9.9M Buy
920
+73
+9% +$510K 1.95% 22
2019
Q3
$5.68M Buy
847
+20
+2% +$136K 2.05% 24
2019
Q2
$5.86M Buy
827
+116
+16% +$672K 1.79% 25
2019
Q1
$3.8M Buy
711
+270
+61% +$1.72M 1.05% 36
2018
Q4
$2.68M Buy
+441
New +$2.11M 1% 31

Other funds holding ATXI

Opaleye Management's ATXI Position: Q4 2020 in Review

Opaleye Management sold out of Avenue Therapeutics (ATXI) in Q4 2020, closing a stake of 875 shares — an estimated $10.7M sold.

Opaleye Management first reported a position in ATXI in Q4 2018 and held it in 8 quarters. The position peaked at $11.1M in Q2 2020. 33 funds tracked by Wall St. Rank hold ATXI as of Q4 2020.

  • Opaleye Management reported no remaining Avenue Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Opaleye Management sold 875 Avenue Therapeutics shares in Q4 2020, an estimated $10.7M.
  • Opaleye Management first reported a position in Avenue Therapeutics in Q4 2018 and held it in 8 quarters.
  • Opaleye Management's Avenue Therapeutics position peaked at $11.1M in Q2 2020.
  • 33 funds tracked by Wall St. Rank held Avenue Therapeutics as of Q4 2020.

Based on Opaleye Management's 13F filing for Q4 2020, filed 12 Feb 2021.